Contraceptive counseling via volunteer reproductive health educators
January 19th 2021Initiation of more effective contraception occurred more often among patients who were seen by a volunteer reproductive health educator during routine visits at a resident obstetrics and gynecology clinic, according to a study published in Maternal and Child Health Journal.
Laparoscopic retrograde hysterectomy in a large uterus
January 19th 2021A retrospective study in the journal Obstetrics & Gynecology and Reproductive Health has concluded that total laparoscopic retrograde hysterectomy (TLreH) for severe endometriosis with obliterated cul-de-sac is both feasible and safe.
Laparoscopy better than imaging for accurate staging in locally advanced cervical cancer
January 11th 2021While no difference was shown in disease-free survival rates between surgical and non-surgical staging methods, laparoscopy benefits patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer. Surgical staging also has a cancer-specific survival benefit, according to a study published in the International Journal of Gynecological Cancers.
Abstract submissions for 2021 SASGOG Virtual Meeting
January 6th 2021The Society for Academic Specialists in General Obstetrics and Gynecology (SASGOG) recently announced its call for abstracts for the 2021 Annual Meeting. The meeting will be held virtually on April 9, 2021 from 1 p.m. to 5:30 p.m. EST.
Navigating the Annual Pregnancy Meeting
January 4th 2021The Society for Maternal-Fetal Medicine’s (SMFM) 2021 Annual Pregnancy Meeting will be held virtually throughout the month of January, with core meeting activities taking place Jan. 25-30. SMFM’s President, Judette Louis, MD, MPH, and Program Committee Chair, Cynthia Gyamfi-Bannerman, MD, MSc, tell readers what they can expect in the new online format.
Improved survival rate in patients with advanced endometrial cancer
December 31st 2020Pembrolizumab plus lenvatinib induced a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy in patients with advanced endometrial cancer after prior systemic therapy in the phase 3 KEYNOTE-775/Study 309 trial.